SEC Form 3 FORM 3

## UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

## **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL

3235-

Estimated average burden

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|  | Address of Repo | 5     | 2. Date of E<br>Requiring S<br>(Month/Day<br>10/06/202         | Statement<br>//Year)  | 3. Issuer Name <b>and</b> Ticker or Trading Symbol Pacira BioSciences, Inc. [ PCRX ]                  |  |  |   |  |  |
|--|-----------------|-------|--|---|---|--|--|---|--|--|
| (Last) (First) (Middle)<br>C/O PACIRA BIOSCIENCES, INC.<br>5401 WEST KENNEDY   |                 |       |  |   | 4. Relationship of Reporting Person(s) to<br>Issuer<br>(Check all applicable)<br>X Director 10% Owner |  |  | 5. If Amendment, Date of Original<br>Filed (Month/Day/Year)   |  |  |
|  | RD, SUITE 8     |       |  |   | Officer (give Other (specify below)   |  | (specify (C  | 6. Individual or Joint/Group Filing<br>(Check Applicable Line)<br>X Form filed by One Reporting<br>Person |  |  |
| (Street)<br>TAMPA  | FL              | 33609 |  |   |   |  |  |   | by More than One<br>Person                                     |  |
| (City)   | (State)         | (Zip) |  |   |   |  |  |   |  |  |
| Table I - Non-Derivative Securities Beneficially Owned   |                 |       |  |   |   |  |  |   |  |  |
| 1. Title of Sec  |                 |       | E  | 2. Amount of Securities<br>Beneficially Owned (Instr.<br>I) |   |  | 4. Nature of Indirect Beneficial<br>Ownership (Instr. 5) |   |  |  |
| Table II - Derivative Securities Beneficially Owned           (e.g., puts, calls, warrants, options, convertible securities) |                 |       |  |   |   |  |  |   |  |  |
|  |                 |       | 2. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |   | 3. Title and Amount of Securities<br>Underlying Derivative Security<br>(Instr. 4)                     |  | 4.<br>Conversior<br>or Exercise<br>Price of              | 5.<br>Ownership<br>Form:<br>Direct (D)  | 6. Nature of<br>Indirect Beneficial<br>Ownership (Instr.<br>5) |  |
|  |                 |       | Date<br>Exercisable  | Expiration<br>Date  | Title   | Amount<br>or<br>Number<br>of<br>Shares | Derivative<br>Security                                   | or Indirect<br>(I) (Instr. 5)   | 5)   |  |

**Remarks:** 

No securities are beneficially owned.

/s/ Kristen Williams, Attorney-in-Fact \*\* Signature of Reporting Person

10/11/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB Number: 0104 hours per response: 0.5

## **POWER OF ATTORNEY**

I, Marcelo Bigal, hereby authorize and designate each of Charles A. Reinhart, III, Kristen Williams and Ned Prusse, signing singly, as my true and lawful attorney-in-fact to:

(1) execute for and on my behalf, in my capacity as an officer and/or director of Pacira BioSciences, Inc. and its affiliates (the "Company"), the Form ID and Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations promulgated thereunder;

(2) do and perform any and all acts for and on my behalf which may be necessary or desirable to complete and execute any such Form ID or Form 3, 4 or 5 and timely file such form with the Securities and Exchange Commission, any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be to my benefit, in my best interest, or legally required of me, it being understood that the statements executed by such attorney-in-fact on my behalf pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

I hereby further grant to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as I might or could do if personally present, with full power of substitutes or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. I hereby acknowledge that the foregoing attorneys-in-fact, in serving in such capacity at my request, are not assuming, nor is the Company assuming, any of my responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until I am no longer required to file the Form ID or Forms 3, 4 and 5 with respect to my holdings of and transactions in securities issued by the Company, unless earlier revoked by me in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, I have caused this Power of Attorney to be duly executed as of this 5<sup>th</sup> day of October 2023.

<u>/s/ Marcelo Bigal</u> Marcelo Bigal